Protocol Labs publishes first BCI Roadmap — identifies regulation-reimbursement gap and 3-9% patient penetration as key barriers
Summary
Protocol Labs' PL Neuro project published the first Brain-Computer Interface Roadmap Series in May 2026, identifying three structural barriers to BCI achieving its potential: first, traditional FDA pathways are misaligned with "living devices" that use adaptive AI algorithms designed to improve post-implantation; second, the regulation-reimbursement disconnect remains a quantified structural risk making novel treatments inaccessible to most patients; and third, established neurotech therapies like DBS and VNS achieve only 3-9% penetration of their addressable patient populations due to physician workflow barriers and the risks of traditional surgical methods.
Why it matters
The Protocol Labs BCI Roadmap is the first strategic framework published by a major technology infrastructure organization for the BCI sector, and the 3-9% DBS/VNS penetration figure is a striking indictment of the structural barriers preventing neurotech from reaching patients. If FDA living device pathways, simultaneous coverage review, and minimally invasive surgical approaches each improve by one category, the sector's addressable patient population could increase by 10-30x without any new scientific discovery.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial